open access

Vol 88, No 2 (2020)
CASE REPORTS
Published online: 2020-04-30
Submitted: 2019-05-19
Accepted: 2019-08-16
Get Citation

Volume-assured pressure support mode plus pirfenidone as resuscitation therapy in patients with exacerbation of idiopathic pulmonary fibrosis

Killen Harold Briones Claudett, Mónica H Briones Claudett, Estupiñan Vargas Domenica, Stalin Rodriguez Garcia, Jaime Benites Solis, Cesar Andrade Cabrera, Michelle Grunauer Andrade
DOI: 10.5603/ARM.2020.0077
·
Pubmed: 32383467
·
Adv Respir Med 2020;88(2):147-152.

open access

Vol 88, No 2 (2020)
CASE REPORTS
Published online: 2020-04-30
Submitted: 2019-05-19
Accepted: 2019-08-16

Abstract

Introduction: Treatment among advanced stage idiopathic pulmonary fibrosis is quite challenging, especially considering that no major evidence has been released about it. This case report demonstrates and discusses the benefit of non-invasive mechanical ventilation in volume-assured pressure support (AVAPS) mode plus pirfenidone based on the relief of a patient’s symptoms in combination with high-resolution computed tomography (HRCT) evidence.
Material and methods: An 83-year-old female patient with multiple hospital admissions within a  six-month period initially presented with cardiac symptoms which were later attributed to a possible exacerbation of her primary diagnosis, idiopathic pulmonary fibrosis.
Conclusion: The addition of non-invasive mechanical ventilation in AVAPS mode plus pirfenidone can improve the survival rates even in patients with current exacerbations of acute respiratory failure due to idiopathic pulmonary fibrosis.

Abstract

Introduction: Treatment among advanced stage idiopathic pulmonary fibrosis is quite challenging, especially considering that no major evidence has been released about it. This case report demonstrates and discusses the benefit of non-invasive mechanical ventilation in volume-assured pressure support (AVAPS) mode plus pirfenidone based on the relief of a patient’s symptoms in combination with high-resolution computed tomography (HRCT) evidence.
Material and methods: An 83-year-old female patient with multiple hospital admissions within a  six-month period initially presented with cardiac symptoms which were later attributed to a possible exacerbation of her primary diagnosis, idiopathic pulmonary fibrosis.
Conclusion: The addition of non-invasive mechanical ventilation in AVAPS mode plus pirfenidone can improve the survival rates even in patients with current exacerbations of acute respiratory failure due to idiopathic pulmonary fibrosis.

Get Citation

Keywords

pirfenidone; idiopathic pulmonary fibrosis; non-invasive ventilator

Supplementary Files (1)
Figure 1
View
275KB
About this article
Title

Volume-assured pressure support mode plus pirfenidone as resuscitation therapy in patients with exacerbation of idiopathic pulmonary fibrosis

Journal

Advances in Respiratory Medicine

Issue

Vol 88, No 2 (2020)

Pages

147-152

Published online

2020-04-30

DOI

10.5603/ARM.2020.0077

Pubmed

32383467

Bibliographic record

Adv Respir Med 2020;88(2):147-152.

Keywords

pirfenidone
idiopathic pulmonary fibrosis
non-invasive ventilator

Authors

Killen Harold Briones Claudett
Mónica H Briones Claudett
Estupiñan Vargas Domenica
Stalin Rodriguez Garcia
Jaime Benites Solis
Cesar Andrade Cabrera
Michelle Grunauer Andrade

References (14)
  1. Ghebre YT, Raghu G. Idiopathic pulmonary fibrosis: novel concepts of proton pump inhibitors as antifibrotic drugs. Am J Respir Crit Care Med. 2016; 193(12): 1345–1352.
  2. Raghu G, Rochwerg B, Zhang Y, et al. American Thoracic Society; European Respiratory society; Japanese Respiratory Society; Latin American Thoracic Association. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015; 192(2): 13–19.
  3. Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016; 194(3): 265–275.
  4. Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011; 37(2): 356–363.
  5. Tzouvelekis A, Ntolios P, Karampitsakos T, et al. Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis: A real-world observational study. Pulm Pharmacol Ther. 2017; 46: 48–53.
  6. Gaudry S, Vincent F, Rabbat A, et al. Invasive mechanical ventilation in patients with fibrosing interstitial pneumonia. J Thorac Cardiovasc Surg. 2014; 147(1): 47–53.
  7. Rush B, Wiskar K, Berger L, et al. The use of mechanical ventilation in patients with idiopathic pulmonary fibrosis in the United States: A nationwide retrospective cohort analysis. Respir Med. 2016; 111: 72–76.
  8. Vianello A, Arcaro G, Battistella L, et al. Noninvasive ventilation in the event of acute respiratory failure in patients with idiopathic pulmonary fibrosis. J Crit Care. 2014; 29(4): 562–567.
  9. Briones Claudett KH. Noninvasive ventilation in the event of acute respiratory failure in patients with idiopathic pulmonary fibrosis: waiting for? J Crit Care. 2014; 29(6): 1128.
  10. Ohkubo H, Kunii E, Moriyama S, et al. Efficacy of combined corticosteroid and pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis after surgery for lung cancer: a case report. Respir Investig. 2015; 53(1): 45–47.
  11. Mallick S. Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit. Respir Med. 2008; 102(10): 1355–1359.
  12. Yokoyama T, Kondoh Y, Taniguchi H, et al. Noninvasive ventilation in acute exacerbation of idiopathic pulmonary fibrosis. Internal Medicine. 2010; 49(15): 1509–1514.
  13. Castria D, Refini RM, Bargagli E, et al. Pulmonary hypertension in idiopathic pulmonary fibrosis: prevalence and clinical progress. Int J Immunopathol Pharmacol. 2012; 25(3): 681–689.
  14. Raghu G, Amatto VC, Behr J, et al. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J. 2015; 46(4): 1113–1130.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl